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Barriers and facilitators to reducing
frequent laboratory testing for patients
who are stable on warfarin: a mixed
methods study of de-implementation in
five anticoagulation clinics
Geoffrey D. Barnes1,2*, Sevan Misirliyan1, Scott Kaatz3, Elizabeth A. Jackson1,2, Brian Haymart1, Eva Kline-Rogers1,
Jay Kozlowski4, Gregory Krol5, James B. Froehlich1,2 and Anne Sales2,6,7

Abstract
Background: Patients on chronic warfarin therapy require regular laboratory monitoring to safely manage warfarin.
Recent studies have challenged the need for routine monthly blood draws in the most stable warfarin-treated patients,
suggesting the safety of less frequent laboratory testing (up to every 12 weeks). De-implementation efforts aim to reduce
the use of low-value clinical practices. To explore barriers and facilitators of a de-implementation effort to reduce the use
of frequent laboratory tests for patients with stable warfarin management in nurse/pharmacist-run anticoagulation clinics,
we performed a mixed-methods study conducted within a state-wide collaborative quality improvement collaborative.
Methods: Using a mixed-methods approach, we conducted post-implementation semi-structured interviews with a total
of eight anticoagulation nurse or pharmacist staff members at five participating clinic sites to assess barriers and
facilitators to de-implementing frequent international normalized ratio (INR) laboratory testing among patients with stable
warfarin control. Interview guides were based on the Tailored Implementation for Chronic Disease (TICD) framework.
Informed by interview themes, a survey was developed and administered to all anticoagulation clinical staff (n = 62) about
their self-reported utilization of less frequent INR testing and specific barriers to de-implementing the standard (more
frequent) INR testing practice.
Results: From the interviews, four themes emerged congruent with TICD domains: (1) staff overestimating their actual
use of less frequent INR testing (individual health professional factors), (2) barriers to appropriate patient engagement
(incentives and resources), (3) broad support for an electronic medical record flag to identify potentially eligible patients
(incentives and resources), and (4) the importance of personalized nurse/pharmacist feedback (individual health
professional factors). In the survey (65% response rate), staff report offering less frequent INR testing to 56% (46–66%) of
eligible patients. Most survey responders (n = 24; 60%) agreed that an eligibility flag in the electronic medical record
would be very helpful. Twenty-four (60%) respondents agreed that periodic, personalized feedback on use of less
frequent INR testing would also be helpful.
(Continued on next page)
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Conclusions: Leveraging information system notifications, reducing additional work load burden for participating patients
and providers, and providing personalized feedback are strategies that may improve adoption and utilization new policies
in anticoagulation clinics that focus on de-implementation.
Keywords: Warfarin, Anticoagulation, Implementation, Quality improvement

Background
Patients on chronic warfarin therapy require regular
international normalized ratio (INR) laboratory monitoring to measure the degree of anticoagulant effect and to
adjust the dose of warfarin. After an initial period of frequent dose titration, many patients achieve a relative
“steady state” where their warfarin dose does not fluctuate significantly [1]. Traditionally, most of these patients
still received a INR blood draw at least every 4 weeks
[2]. However, recent observational and prospective,
randomized studies have challenged the need for such
frequent blood draws in the most stable warfarin-treated
patients, demonstrating safety with INR blood draws
every 12 weeks [3, 4]. While supported by guidelines,
adoption of a less frequent laboratory testing practice
has not been widely adopted [2, 5].
Beginning in 2013, six anticoagulation clinics participating in an anticoagulation clinic quality improvement
collaborative identified INR testing frequency as a quality improvement focus [6]. After extensive discussion at
collaborative-wide quarterly meetings, individual anticoagulation clinics developed eligibility criteria for less
frequent INR testing (Table 1). These criteria determined
the number of INR tests that must be within the target
range before a scheduled INR test could be extended beyond the traditional 4-week window. Based on these
site-specific criteria, reporting tools were developed to
provide real-time feedback to anticoagulation clinic staff
Table 1 Extended INR testing policies by anticoagulation clinic
Definition of “stable
warfarin patient”

Maximal allowed
INR testing interval

Clinic 1

12 weeks without maintenance
dose change and no out of
range INRs

10 weeks

Clinic 2

6 months without a weekly dose
change and no INRs >10% above
/below therapeutic range

12 weeks

Clinic 3

6 months without a weekly dose
change and no INRs >10% above
/below therapeutic range (both
have to be met)

6 weeks

Clinic 4

10 weeks of no INRs > 10% above
/below therapeutic range

6 weeks

Clinic 5

4 months without any INRs >10%
out of range and no weekly dose change

6 weeks

about the utilization of less frequent INR testing (defined as a plan to re-check an INR ≥ 5 weeks from the
most recent INR laboratory test). Overall rates of less
frequent INR testing were reported and discussed at
each subsequent quarterly meeting. However, utilization
of this practice plateaued around 50–60% of eligible patients by the end of 2015.
The Tailored Implementation for Chronic Disease
(TICD) framework was developed as a comprehensive,
integrated checklist of determinants of implementation
success, reconsolidating across 12 different reviews of
implementation determinants [7]. By integrating elements from other commonly used frameworks, e.g., the
Consolidated Framework for Implementation Science
and the Theoretical Domains Framework, it aims to be
an easily used checklist to identify determinants of practice for implementation strategy development and program evaluation [8, 9]. The TICD developers intended it
to be used as a screening tool that can help identify implementation determinant that warrant further in-depth
investigation and to facilitate tailoring of more effective
change interventions and evaluation.
De-implementation, also known as de-adoption, is commonly defined as the reduction in use of low-value clinical
practices [10]. As is highlighted by the recent Choosing
Wisely campaign, many experts recommend against the
routine use of common, but low-yield, clinical practices.
These practices can cause unnecessary anxiety, harm, and
cost for patients and the healthcare system [11]. Yet,
specific barriers and facilitators to de-implementation of
low-yield practices have not been thoroughly examined.
And the use of implementation frameworks, such as the
TICD framework, to evaluate de-implementation effort
remains inadequately studied [10, 12].
The Michigan Anticoagulation Quality Improvement
Initiative (MAQI2) is a collaborative of six anticoagulation clinics in Michigan aimed at improving the delivery
of anticoagulation care with the support of Blue Cross
Blue Shield of Michigan [13]. The collaborative is financially supported by the state-wide health insurer Blue
Cross-Blue Shield of Michigan. The collaborative identifies important quality improvement efforts to work on
jointly, shares best practices at quarterly meetings, and
reviews chart abstracted data to monitor progress on the
various quality improvement efforts. Patients newly
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starting on warfarin who are referred to one of the participating anticoagulation clinics are eligible to have their
demographic and medical information abstracted into
the MAQI2 registry. All data elements are manually
abstracted from the medical chart by trained chart
abstractors using pre-defined data elements. All INR lab
tests, warfarin weekly doses, and communication between the anticoagulation clinic and the patient/family
are abstracted into the registry.
We set out to explore barriers and facilitators for a deimplementation effort for patients with stable warfarin
control who are managed at one of the anticoagulation
clinics participating in MAQI2. The de-implementation
effort (a new clinic policy) was targeted at anticoagulation clinic providers (nurses and pharmacists) with a
goal of reducing frequent INR laboratory testing for patients with stable warfarin control. These nurses and
pharmacists were asked to review each patients’ record
for eligibility (i.e., stable warfarin management over sequential INR laboratory tests) to have less frequent INR
laboratory tests. Each anticoagulation clinic developed
their own specific policy outlining the specific eligibility
criteria and maximal duration between scheduled INR
laboratory tests (Table 1). This practice was to be carried
out anytime an anticoagulation clinic staff member
interacted with an eligible patient, which usually occurs
when the staff member reviews the most recent INR
laboratory test results and provides warfarin dosing
recommendations to the patient.
Based on clinical experience, we hypothesized that
technological barriers (e.g. difficulty identifying prior
INR values in the electronic medical record) would exist
to identifying appropriate patients for reduced INR testing frequency and that most anticoagulation clinic staff
would underestimate their personal utilization of a less
frequent INR testing.

Methods
Study design

We employed a mixed-methods approach for this study.
As is recommended by the TICD authors, we reviewed
the framework’s exhaustive checklist of twelve domains
and 57 associated determinants of practice [7]. We selected the domains and determinants of practice that we
felt were most relevant to the de-implementation of
frequent INR laboratory testing among stable warfarin
patients. From these domains and determinants, we developed an interview guide aimed at assessing specific
barriers and facilitators to a de-implementation process
(Additional file 1).
Based on the most salient themes that emerged
from the interviews, a brief survey was developed
(Additional file 1).
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Research setting and sampling strategy

Anticoagulation clinic staff (nurses and pharmacists) from
all MAQI2 sites were invited to participate in the study.
For this project, one of the MAQI2 sites elected to not
participate in anticoagulation staff interviews or the survey, resulting in five participating sites. One or two nurses
or pharmacist staff from the five participating MAQI2
sites participated in semi-structured interviews. The anticoagulation clinic leadership selected “representative” staff
members (not necessarily the highest or lowest performing staff members). All nurses and pharmacists at the participating anticoagulation clinics (including those who
participated in the interviews) were then invited to participate in the online survey.
Data collection methods

After 2 years of consortium-wide discussion and review
of INR testing frequency data, a mixed-methods study
was undertaken to better understand the barriers and facilitators to less frequent INR testing for eligible patients
on warfarin therapy. These interviews were conducted
by two team members (GDB and SM) under the guidance of a third team member (AS) between May and
July 2016. Interviews were conducted either in person or
by phone.
All nursing and pharmacist staff at the five participating anticoagulation clinics were invited to anonymously
complete a brief online survey. This survey assessed staff
self-reported use of less frequent INR testing within the
last 6 months (answer choice ranges of 0–20%, 21–40%,
41–60%, 61–80%, and 81–100% of the time), selfreported use of less frequent INR testing for the last 10
eligible patients, attitudes about periodic feedback, selfreported frequency checking eligibility (answer choices
never, almost never, sometimes, almost every time, and
every time), and perceived helpfulness of an electronic
medical record flag for patient eligibility (answer choices
not helpful, somewhat helpful, and very helpful). Survey
invitations were sent on 29 August 2016 with one
reminder e-mail sent on 7 September 2016.
Data analysis methods

Interviews were audio recorded and study team members
conducted framework analysis, coding into the TICD
framework domains [14, 15]. Salient themes were identified by both team members who conducted the interviews
(GDB and SM) and coded the transcripts. Frequency statistics were calculated for survey responses.
Comparing survey self-response to actual performance
data

To compare self-reported rates to actual rates of less frequent INR testing, we used data from the MAQI2 registry between January and June of 2016. Clinic-level rates
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of less frequent INR testing were calculated based on
the individual anticoagulation clinic protocols (Table 1)
and excluded any patients on home INR testing, with a
ventricular assist device implanted, or who opted out of
the less frequent INR testing practice. We used the
midpoint of the survey response range (e.g., 50% for the
survey response option of 40–60%) for point estimates.
To generate confidence intervals (CI) around our summary point estimates, we used the lower and higher
boundary from the survey response options (e.g., 40%
and 60%) in repeat calculations.
Regulatory review

Institutional review for patient data collection and analysis has been approved at all participating sites, including the University of Michigan (coordinating center).
This project was reviewed and deemed “not regulated”
by the University of Michigan Institutional Review Board
since it did not meet regulatory definitions of “research”
and instead was categorized as a quality improvement
project.

Results
Eight semi-structured interviews were conducted, seven
with anticoagulation nurses, and one with a pharmacist.
Four main themes emerged from these interviews. First,
all interviewees reported being highly compliant with offering less frequent INR testing to eligible patients. They
were surprised to hear that the actual overall utilization
rates of less frequent INR testing for eligible patients
were closer to 50–60% and not 80–100%, which they
had predicted based on their own experience and belief
about practice patterns. This linked with the TICD domain of individual health professional factors.
The second theme identified was variable barriers to
appropriate patient engagement (TICD domain incentives and resources—which could be considered ‘dis-incentives and resources’ in this context). These barriers
most often related to the individual health care center’s
electronic medical record and/or policies. The first example centers on available data and ease of access to
that data within the electronic medical record. Some
centers offer simple flowsheets of INR results (at least
5–6) that are easy to review and identify trends. Other
centers required multiple clicks within different computer screens to access these data. The second example
of this barrier involves the prerequisites required before
an anticoagulation clinic staff member can begin using a
less frequent INR testing schedule for an individual patient. Some centers, but not all, use specialized processes
or required extensive and additional patient education
before allowing less frequent INR laboratory testing
schedules. These two examples of barriers to appropriate
patient engagement (inability to easily review INR labs
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and need for extra education or a separate process) were
commonly cited, particularly on busier days in the anticoagulation clinic. Other interviewees identified a need
for increased patient education, especially for patients
with longer warfarin-treatment experience as such
patients were often previously told that 4 weeks was the
maximum interval between INR blood draws for safety
reasons.
Third, the interviewees expressed broad support for an
electronic medical record flag for potential extended
INR testing eligibility (TICD domain incentives and resources). Interviewees acknowledged that while forgetting to look for eligibility was not the most common
barrier, it likely contributed to overly frequent INR testing among patients with stable warfarin control.
Finally, all interviewees agreed the personalized
provider-level feedback on use of less frequent INR testing for eligible patients would be very helpful (TICD domain individual health professional factor). It was noted
that many people believe that they are always compliant
while others are the “problem.”
Several additional themes were identified throughout
the interviews. All interviewees noted that there was incentive for both the clinical staff and the patients to reduce the number of INR tests being ordered. For staff
members, this lead to overall reductions in work load.
For patients, less frequent blood draws were often seen
as a reward for prior good INR control. Work load issues were particularly salient for the interviewees. They
acknowledged that increased work load in the short
term, such as having to spend extra time doing patient
education or documentation to “enroll” a patient in the
less frequent INR testing protocol, was inversely related
to their likelihood to decrease INR testing frequency for
patients with stable warfarin control. They acknowledged that this was somewhat counter-intuitive as less
frequent INR testing decrease work load in the long
term, but that short-term work load increases are a significant barrier. Finally, when asked about how anticoagulation clinic staff identify eligible patients for less
frequent INR testing, staff members were able to identify
their clinic’s process for determining eligibility. However,
there was always heavy emphasis on the patients that
were not eligible (e.g., patients on home INR testing or
patients with ventricular assist devices). This focus on
identifying patients not eligible, rather than eligible, may
indicate some level of staff reluctance to reduce the INR
testing frequency for patients even when patients would
otherwise qualify based on stable warfarin control.
Equally, it may reflect some challenges that providers
have in identifying eligible patients at the point of care.
A brief, 10-question survey was completed by 40 of
the 62 invited nurse and pharmacist staff members (65%
completion rate). Most respondents (n = 21; 54%) had
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more than 5 years of anticoagulation clinic experience.
The majority of respondents (n = 32; 80%) were anticoagulation nurses while the remaining (n = 7; 18%) were
pharmacists or did not report their clinical training (n =
1; 2%). Data on survey non-responders was not available.
When asked to estimate a percentage of eligible patients
who received a less frequent INR testing in the last
6 months, 16 (40%) selected 81–100% of the time while
only 8 (20%) selected 0–20% of the time (Fig. 1). When
asked to estimate how many of the prior 10 eligible
patients received less frequent INR testing, the mean response was 7.8 (SD 2.4). Eighteen (45%) of respondents
indicated that they always review a patient’s chart for
less frequent INR testing eligibility while 16 (40%)
reported doing this almost every time. A majority (n =
24; 60%) agreed that a flag in the electronic medical record would be very helpful in highlighting potentially eligible patients for less frequent INR testing. Twenty-four
(60%) of respondents agreed that periodic, personalized
feedback on INR testing frequency would be helpful.
When asked about the number one barrier to routinely
reducing INR testing frequency for eligible patients, survey responders frequently noted time constraints, need
for additional or non-standardized documentation, staff
forgetfulness, concerns for elderly patients, and patients
requesting to stay with shorter intervals.
Based on audit data from the MAQI2 registry of patients on chronic warfarin therapy, less frequent INR
testing was offered to 580 of 921 (63.0%) eligible MAQI2
patients over the first 6 months of 2016. The survey
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responders indicated that they offered less frequent INR
testing to eligible patients 56% of the time (CI 46–66%).

Discussion
This mixed-methods study of anticoagulation clinic
nurses and pharmacists highlights important considerations for any new de-implementation policy or clinical
practice at the provider level. With regards to reducing
the frequency of INR testing for patients with stable
warfarin control, this includes easy access to INR lab
trends with flags for potentially eligible patients, minimizing extra work or patient education that occurs when
selecting the next scheduled INR testing date, and providing individualized feedback on appropriate INR testing frequency. The survey responses enhance the
credibility and of the interview findings.
One other health system has published their experience with a similar de-implementation effort to reduce
frequent INR tests among patients with stable warfarin
control [16, 17]. However, they did not report on how
frequently their staff scheduled the next INR test more
than the standard 4 weeks into the future for eligible
patients or the barriers and facilitators to their deimplementation effort. Within the five centers participating in our current project, a significant amount of education was provided to the anticoagulation staff by their
medical directors prior to and during the roll out of this
new practice of less frequent INR testing for patients
with stable warfarin control. Continuous monitoring,
however, demonstrated that a reduction in INR testing

Fig. 1 Self-reported Frequency of Extended INR Testing for Stable Warfarin Patients
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was limited. Further, staff training efforts only had modest impact on overall de-implementation effort. The
current study highlights important barriers beyond “staff
training” that likely contribute to below goal utilization
rates and success at de-implementation of current practice patterns.
By using the TICD determinants of implementation,
we identified specific barriers in addition to “provider
knowledge” that likely influence provider behavior [7].
In the case of reducing unnecessary INR laboratory tests
for patients with stable warfarin treatment, these align
with “feasibility and accessibility”, “compatibility and effort”, “knowledge about a provider’s own practice”, “selfmonitoring or feedback”, and “information system barriers” from the TICD determinants. Comparing the selfreported survey data to the actual reduction in INR testing finds reasonable accuracy in the self-reported data.
However, the semi-structured interviewees were surprised to hear the actual rate of less frequent INR testing
among eligible patients, perhaps suggesting that these
were a somewhat biased group of selected anticoagulation staff members. In contrast to prior studies suggesting clinician overestimation of guideline-adherence
practice, our study suggests that these clinicians either
accurately or slightly underestimate the frequency with
which they reduced INR testing frequency [18]. Still,
providing personalized and timely feedback is important
to inform staff of their performance and opportunities
for improved patient care. While none of these barriers
are novel or new to implementation researchers, they
may not be universally considered by anticoagulation
clinic directors who desire to implement local policy or
procedural change. This was certainly the case within
the five participating centers for this study.
In response to these findings, we are developing tools
within our electronic health records to automatically
screen for and flag patients who are likely eligible for less
frequent INR testing, based on 4 months of continuously
in range INR values. We anticipate that this information
system change will help address concerns about difficulty
reviewing all prior INR values easily and any unintended
forgetfulness that can occur when staff are busy with
many patient labs to review and act upon. We are also developing systems to provide more personalized feedback
at each clinical site to individual anticoagulation clinic
staff about their recent patients who were eligible for less
frequent INR testing, and whether or not it was offered
during the encounter. We continue our anticoagulation
staff education efforts, reviewing utilization and safety
data from all MAQI2 sites to address any staff concerns.
We believe this may be critical for the 20% of survey respondents who reported rarely attempting to reduce INR
testing frequency (Fig. 1). Finally, we are working to
remove barriers to reducing INR testing frequency,
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including reducing the amount of extra patient education
or clinical documentation that is needed for an anticoagulation nurse or pharmacist to begin using this process for
eligible patients. Instead, we are focusing on improving
the patient education material to highlight that INR testing intervals may be extended beyond 4 weeks once patients have established a very stable treatment regimen.
Our study has several important strengths, including
the use of a mixed-methods design which allows for deeper understanding of potential practice barriers and
breadth of representation through survey work. However,
important limitations must be considered when interpreting these results. First, we were unable to interview all
anticoagulation clinic staff, and therefore the themes identified through the interviews may not represent the entire
spectrum of experiences. However, with the eight interviews performed, we felt that thematic saturation was
reached, and that these findings were largely supported in
the broader anticoagulation staff survey. Second, while we
could assess barriers across five diverse anticoagulation
clinics, each of these clinics is located in southern Michigan and participates in an insurer-sponsored quality improvement collaborative. Additionally, we were only able
to interview a single pharmacist, limiting comparisons between nurses and pharmacists working in anticoagulation
clinics. Finally, no formal triangulation analysis was performed. These may limit generalizability to all anticoagulation clinics in the United States of America or beyond.

Conclusions
In summary, using a mixed-methods approach we identified key barriers and facilitators to a de-implementation
effort to reduce frequent INR laboratory tests among patients with stable warfarin control in five anticoagulation
clinics and their staff. Beyond providing staff education, leveraging information system notifications, reducing additional work load burden for participating patients and
anticoagulation clinic staff, and providing personalized
feedback to anticoagulation clinic staff appear to be key
strategies that may improve adoption and utilization of a
policy that requires de-implementation of an existing
practice. Evaluating the effect of these interventions and
the relationship of these barriers to other anticoagulation
clinic policy changes should be explored in future work.
Additional file
Additional file 1: Semi-structured Interview Guide. (DOCX 20 kb)
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